Pfizer (PFE) Short-Term Debt issuances (2016 - 2025)
Historic Short-Term Debt issuances for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $6.0 million.
- Pfizer's Short-Term Debt issuances fell 9992.66% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year decrease of 6132.84%. This contributed to the annual value of $8.9 billion for FY2024, which is 9683.98% up from last year.
- Per Pfizer's latest filing, its Short-Term Debt issuances stood at $6.0 million for Q3 2025, which was down 9992.66% from -$517.0 million recorded in Q2 2025.
- In the past 5 years, Pfizer's Short-Term Debt issuances registered a high of $8.2 billion during Q3 2024, and its lowest value of -$2.0 billion during Q1 2024.
- Moreover, its 5-year median value for Short-Term Debt issuances was -$9.5 million (2021), whereas its average is $1.6 billion.
- Data for Pfizer's Short-Term Debt issuances shows a peak YoY increase of 648671.88% (in 2024) and a maximum YoY decrease of 100221.24% (in 2024) over the last 5 years.
- Pfizer's Short-Term Debt issuances (Quarter) stood at $265.0 million in 2021, then skyrocketed by 1366.79% to $3.9 billion in 2022, then rose by 19.14% to $4.6 billion in 2023, then soared by 76.53% to $8.2 billion in 2024, then crashed by 99.93% to $6.0 million in 2025.
- Its Short-Term Debt issuances stands at $6.0 million for Q3 2025, versus -$517.0 million for Q2 2025 and -$386.0 million for Q1 2025.